Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3049% above fair value
$68.53−0.78 (-1.13%)
Close on Nov 16, 2026Market cap $39.40BP/E 38.9Yield –
Royalty Pharma total assets
Total assets on the balance sheet at the end of each period.
Royalty Pharma's total assets was $19.82B at Jun 30, 2026. For fiscal 2025 it was $19.62B, up 7.7% from the year before. The highest annual figure on record is $19.62B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.62B | +7.7% |
| FY2024 | Dec 31, 2024 | $18.22B | +11.2% |
| FY2023 | Dec 31, 2023 | $16.38B | -2.6% |
| FY2022 | Dec 31, 2022 | $16.81B | -4.0% |
| FY2021 | Dec 31, 2021 | $17.52B | +9.3% |
| FY2020 | Dec 31, 2020 | $16.02B | +28.7% |
| FY2019 | Dec 31, 2019 | $12.45B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.82B | +8.2% |
| Q1 FY2026 | Mar 31, 2026 | $19.82B | +12.5% |
| Q4 FY2025 | Dec 31, 2025 | $19.62B | +7.7% |
| Q3 FY2025 | Sep 30, 2025 | $19.35B | +7.2% |
| Q2 FY2025 | Jun 30, 2025 | $18.32B | +3.8% |
| Q1 FY2025 | Mar 31, 2025 | $17.61B | +9.2% |
| Q4 FY2024 | Dec 31, 2024 | $18.22B | +11.2% |
| Q3 FY2024 | Sep 30, 2024 | $18.04B | +13.8% |
| Q2 FY2024 | Jun 30, 2024 | $17.66B | +3.1% |
| Q1 FY2024 | Mar 31, 2024 | $16.13B | -5.5% |
| Q4 FY2023 | Dec 31, 2023 | $16.38B | -2.6% |
| Q3 FY2023 | Sep 30, 2023 | $15.86B | -10.3% |
| Q2 FY2023 | Jun 30, 2023 | $17.12B | -3.5% |
| Q1 FY2023 | Mar 31, 2023 | $17.07B | -1.8% |
| Q4 FY2022 | Dec 31, 2022 | $16.81B | -4.0% |
| Q3 FY2022 | Sep 30, 2022 | $17.67B | -0.3% |
| Q2 FY2022 | Jun 30, 2022 | $17.74B | +7.4% |
| Q1 FY2022 | Mar 31, 2022 | $17.38B | +9.2% |
| Q4 FY2021 | Dec 31, 2021 | $17.52B | +9.3% |
| Q3 FY2021 | Sep 30, 2021 | $17.73B | +10.9% |
| Q2 FY2021 | Jun 30, 2021 | $16.51B | +5.3% |
| Q1 FY2021 | Mar 31, 2021 | $15.91B | +27.8% |
| Q4 FY2020 | Dec 31, 2020 | $16.02B | – |
| Q3 FY2020 | Sep 30, 2020 | $15.99B | – |
| Q2 FY2020 | Jun 30, 2020 | $15.69B | – |
| Q4 FY2019 | Dec 31, 2019 | $12.45B | – |
See a number that looks wrong?